The article argues that Amgen combines growth, income and stability. In the second quarter, revenue rose 10% year over year to $10.1 billion, and 22 products posted at least double-digit sales growth despite the upcoming loss of patent exclusivity for denosumab. Newer therapies such as Tezspire, Tepezza and Imdelltra are driving growth, and MariTide, an investigational GLP-1 medicine in Phase 3 studies, could launch within a few years. The stock rose about 16% in 2022 when broader equities fell, and the dividend has grown 152% over the past decade. With a trailing-12-month cash payout ratio of 51.9% and a forward yield of 2.3% versus the S&P 500's average of 1.1%, the author considers Amgen suitable for income-focused investors.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Amgendividendshealthcarepharmaceuticals
Open a keyword to see other news on the same topic.
Related tickers and likely impact
NVDA
• NeutralNvidia
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Semiconductors |
| Market cap | $5.1T |
| Close on 10/30/2026 | 204.81 |
| Change that session | -4.14% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months, compared with 12.7 months for Imfinzi alone, in patients whose cancer had not progressed after initial Imfinzi and chemotherapy. Nearly 80% of patients on the combination were alive at one year, versus 53% on Imfinzi alone. Imdelltra posted $288 million in second-quarter sales, up 115% year over year, after $627 million in global sales in 2025. Amgen said the results suggest earlier use of the drug could meaningfully alter the course of the disease, though the trial did not compare the combination with other first-line treatments.
- Amgen vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ?
This comparison pits Amgen (AMGN) against Bristol Myers Squibb (BMY), with Amgen focused on biologics and BMY strong in oncology and hematology. In FY 2025, Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion, a net margin near 21%, and free cash flow of nearly $8.1 billion. BMY generated revenue of about $48.2 billion, nearly flat, with net income of about $7.1 billion, a net margin near 14.6%, and free cash flow of about $12.8 billion. Amgen faces drug pricing pressure, an IRS tax dispute and biosimilar competition, while BMY relies heavily on Eliquis, which faces generic competition. The article describes BMY as cheaper, but says much of the difficulty appears priced in, so it is not an obvious buy right now.
- Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
The article compares Amgen and Gilead Sciences, two large biotech companies that pay dividends. Amgen's forward dividend yield tops 2.2%, while Gilead's is slightly below 2.1%, but Gilead has the lower payout ratio at 43.5% versus Amgen's 60.9%. Gilead also trades at 15.6 times forward earnings against Amgen's 16.7. Amgen's product sales rose 9% and it has 17 drugs on track to be blockbusters this year, versus 8% growth and eight drugs at Gilead. The author says Amgen fits income investors focused on yield and growth, while Gilead suits those prioritizing safety or value, and many investors could hold both.
- 2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
The article examines Johnson & Johnson (JNJ) and Amgen (AMGN), two dividend stocks that have outperformed the market in 2026. For J&J, revenue and earnings beat expectations and guidance was slightly raised, but its medtech unit faces weaker Impella demand and a Class 1 recall in the U.S.; the article still sees long-term prospects intact, citing new drug launches, the OTTAVA surgical system, a proposed $5.5 billion talc settlement and a 64-year dividend increase streak. Amgen's second-quarter revenue rose 10% to $10.1 billion despite FDA moves to remove Tavneos and falling denosumab sales after losing exclusivity. The article says growth drivers such as Tezspire, Tepezza and the MariTide obesity candidate could offset these headwinds.
- Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
The article compares three drugmakers: Biogen (BIIB), Amgen (AMGN) and Gilead (GILD). Biogen closed at $225.71 on October 9 after returning 30.5% over six months, Amgen closed at $414.87 (up 18.6%), and Gilead closed at $151.17 (up 8.8%). Gilead posted a net loss of more than $3 billion over the past year yet generated the most cash in the group and the highest return on assets at 14.09%, which the author attributes to accounting charges. Revenue grew roughly 10% at Gilead and Amgen versus 3.40% at Biogen, whose earnings fell 84.60% in the latest quarter. Biogen has the lowest forward P/E at 13.65 times, versus 15.29 for Gilead and 16.94 for Amgen, and the author sees Gilead as worth its small premium.
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
Johnson & Johnson recorded about $7 billion in charges in Q3 2026, including a proposed talc litigation resolution and expenses tied to the Firefly Bio transaction and a Sail Biomedicines collaboration, which weighed heavily on earnings. Despite this, the company raised its full-year revenue and earnings guidance, with quarterly revenue up nearly 6% while GAAP earnings per share fell about 96%. The proposed talc settlement totals $5.5 billion, with an initial $3 billion payment due in 2027 and the remainder paid in later years. The author views the settlement as a net positive that could let J&J focus on long-term growth, noting that healthcare spending tends to hold up in recessions. J&J has increased its dividend for 64 consecutive years, which the author cites as evidence of the company's resilience.
Related markets
Latest news
- 5 insightful analyst questions from Microsoft’s Q3 earnings call
Microsoft's third quarter beat Wall Street expectations, with revenue of $92.28 billion versus $90.64 billion expected (1.8% beat) and GAAP EPS of $4.92 versus $4.72 (4.3% beat). Management credited wide adoption of its cloud and AI offerings, particularly Copilot and Foundry, for rapid growth in enterprise demand, and CEO Satya Nadella said automated tasks have nearly doubled since July. Gross margin was 67.8%, down from 69% a year earlier, while operating margin of 49.8% was in line with the prior year; market capitalization stood at $3.94 trillion. The article also reviews five analyst questions from the call, covering long-term return drivers, Azure growth, enterprise versus digitally native AI workloads, operating margin sustainability, and usage-based billing outside coding.
- If a Recession Is Coming, History Says Utilities Aren't Safe, Just "Less Bad." Here's the Data.
The article notes that although the strict recession definition (two consecutive quarters of negative GDP growth) has not been met this year, investors often turn to defensive sectors such as utilities. Using the State Street Utilities Select Sector SPDR ETF (XLU) as a benchmark across four recessions since its launch, it finds utilities fell less than the broader market but were not safe: during the tech bubble bust (2000–02), the ETF slid 34.3% versus 42.4% for the S&P 500. During the global financial crisis (2007–09), it lost 42.5% versus nearly 56% for the S&P 500. In 2020, the ETF gained just 0.6% while the S&P 500 rose 18.4%; in 2022, the ETF gained 1.4% as the S&P 500 fell 18.2%. The author concludes the most reasonable expectation for utilities in a severe downturn is to perform 'less bad'.
- Zscaler (ZS) Stock May Be 14% Undervalued As AI Security Demand Builds
Zscaler is back in focus amid cybersecurity headlines and AI security concerns, and the article asks whether its share price is supported by the cash flow the business can generate. The stock delivered a three-year total return of 44.7%, and new attention on its Zero Trust Exchange and work securing AI workloads, including integration with NVIDIA's OpenShell Reference Architecture, could shape expectations for turning demand into durable cash generation. Over the last twelve months, Zscaler produced about $805.9 million in free cash flow, and a discounted cash flow model based on analyst forecasts sits modestly above the current share price of $237.82. The article attributes the gap between price and that estimate more to sector sentiment after a peer's weaker margins than to a decline in Zscaler's cash generation, while an 11.6x price-to-sales multiple offers a different valuation view.
- Is Adobe the Ultimate Buy-on-the-Dip Stock?
The article argues Adobe faces the risk of being replaced by AI-generated images, though the company is adding AI tools to its software. Its subscription revenue has kept growing at a slow but steady pace, with little change from the 2022 growth rate, while the stock is down about 60% from its late 2021 peak. Adobe now trades at 11 times forward earnings, a level that reflects market skepticism. The author doubts Adobe can achieve 20% to 30% growth or regain its valuation, and even a rise to 20 times forward earnings would amount to a single doubling followed by market-average growth. Although the author thinks the outlook is not as bad as the market believes, investors do not need to hold Adobe stock when many solid AI stocks are available.
- Is Apple a Top Tech Stock to Buy Now?
The article notes Apple is up about 27% in 2026 and has lifted revenue growth above 10% year over year, but argues that growth may fade once the current smartphone upgrade cycle ends. It notes that Apple's stock has twice exceeded 40 times earnings over the past decade, and each time the valuation fell by 25% to around 30 times earnings or lower, a pattern the author expects could repeat in 2027. With analysts projecting about 10% revenue growth in 2027, the author sees Apple growing at roughly the S&P 500's average pace, while the index trades at 23.2 times earnings. The author therefore concludes there are better stocks than Apple to consider now and that Apple's valuation is unlikely to rise much further from current levels.
- A Stock Market Correction Could Be Coming. Here's Why I'm Still Investing.
The S&P 500's Shiller cyclically adjusted P/E is now about 41, its highest level since August 2000, when it stood at 41.89 and the market had already entered the early stage of a bear market that lasted until November 2022. The author says it is impossible to know whether a correction is imminent and that the market could keep rising. The author suggests keeping portfolios diversified, rebalancing if they are top-heavy in tech, scaling back positions in stocks valued well above their typical ranges, and adding value, dividend, and high-quality stocks. The author also views discounted tech, AI, or growth stocks as worth examining, provided investors research why they are cheap and whether their fundamentals remain strong.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.